Skip links

Brineura® (cerliponase alfa)

Full Name Brineura® (cerliponase alfa)
Drug Brineura
Manufacturer BioMarin Pharmaceutical Inc.
Route of Administration Intraventricular
Site of Care Healthcare Facility
Approved Indication Indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency
Disease Ceroid Lipofuscinosis (C2LN)
Therapeutic Area Neurology
Enrollment Form Link Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website